B-cell Acute Lymphoblastic Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Acute Lymphoblastic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-05-29Clinical Trial Update: Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL [Phase 2, Phase 3]
This document provides an update on a Phase 2/Phase 3 trial evaluating intravenously administered autologous CD19 CAR-T cells for relapsed o…
-
CLINICAL_TRIALS research · 2025-05-23Clinical Trial Update: Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1 [Phase 2]
A Phase 2 clinical trial evaluating Inati-cel (CNCT19) CAR-T therapy for MRD-positive B-cell acute lymphoblastic leukemia patients in first …
-
CLINICAL_TRIALS research · 2025-05-22Clinical Trial Update: A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. [Phase 1]
A Phase 1 study evaluating the safety, tolerability, and preliminary efficacy of B019 Injection in patients with relapsed or refractory B-ce…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL [Phase 2]
A Phase 2 study evaluating huCART19 for very high-risk pediatric B-cell acute lymphoblastic leukemia has completed and results have been pos…
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia [Phase 1]
This Phase 1 trial update reports completion of a study evaluating the combination of palbociclib and dexamethasone in relapsed or refractor…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-05-15Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia [NA]
A clinical trial update indicates that JY231 injections are being studied for relapsed/refractory B-cell acute lymphoblastic leukemia and B-…
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: Blinatumomab Bridging Therapy for BALL [Phase 2]
Phase 2 trial evaluating blinatumomab as bridging therapy for B-cell acute lymphoblastic leukemia was terminated; results have been posted.
-
CLINICAL_TRIALS research · 2025-05-04Clinical Trial Update: The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL [Phase 2]
Phase 2 study evaluating elimination of total body irradiation for NGS-MRD negative children, adolescents, and young adults with B-cell acut…
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: "Triple Negative" Adult B-cell Acute Lymphoblastic Leukemia - TRINEG-ALL
A clinical trial update for TRINEG-ALL investigating triple-negative adult B-cell acute lymphoblastic leukemia is currently recruiting. Spon…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies [Phase 1]
A Phase 1 clinical trial update evaluating the safety and efficacy of DuoCAR20.19.22-D95 in adults with relapsed or refractory B-cell malign…
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Observational Study of Blinatumomab
An observational study evaluating Blinatumomab (Blincyto) in routine clinical practice has completed.
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors [Phase 1, Phase 2]
Ongoing Phase 1/Phase 2 trials are evaluating CAR-T cell therapy for relapsed or refractory malignant hematologic tumors, including aggressi…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell Leukemia [NA]
A clinical trial entry for JY231 injection in relapsed or refractory B-cell acute lymphoblastic leukemia, currently not yet recruiting.
-
CLINICAL_TRIALS research · 2025-03-20Clinical Trial Update: Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL [Phase 2]
Phase 2 clinical trial evaluating short-course blinatumomab for eradication of measurable residual disease in B-cell acute lymphoblastic leu…
-
CLINICAL_TRIALS research · 2025-03-12Clinical Trial Update: Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia [NA]
A clinical trial (S1904) from Peking University People's Hospital is investigating whether to bridge to allogeneic hematopoietic stem cell t…
-
CLINICAL_TRIALS research · 2025-02-25Clinical Trial Update: a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a CD19 and CD22-targeted Prime CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblasti…
-
CLINICAL_TRIALS research · 2025-02-07Clinical Trial Update: Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol [Phase 2, Phase 3]
A multicenter Phase 2/3 pediatric trial protocol for newly diagnosed intermediate/high risk B-cell acute lymphoblastic leukemia is currently…
-
CLINICAL_TRIALS trial_result · 2025-02-05Clinical Trial Update: Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL [Phase 1]
A Phase 1 trial evaluating blinatumomab in combination with HLA-mismatched cellular therapy for relapsed/refractory CD19+ B-cell acute lymph…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment
A completed clinical trial evaluated the outcomes of adults with relapsed/refractory B-cell acute lymphoblastic leukemia treated with inotuz…
-
CLINICAL_TRIALS research · 2025-01-27Clinical Trial Update: Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia [EARLY_Phase 1]
A Phase 1 trial evaluating donor-derived CD19 CAR-T cells for relapsed/refractory B-cell acute lymphoblastic leukemia is currently recruitin…
-
CLINICAL_TRIALS trial_result · 2025-01-23Clinical Trial Update: The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia [EARLY_Phase 1]
Early-phase clinical trial update on RD06-03 CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia; the study is cu…
-
CLINICAL_TRIALS research · 2025-01-15Clinical Trial Update: Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1 [Phase 2]
Phase 2 study of Inati-cel (Inaticabtagene Autoleucel) for newly diagnosed B-cell acute lymphoblastic leukemia in CR1 is not yet recruiting.
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL [Phase 2]
A Phase 2 clinical trial evaluating CAR-T-19 therapy for CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia is current…
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial update on locally manufactured CAR T-cell products for multiple B-cell malignancies, including B-cell lymphoma and B-…
-
CLINICAL_TRIALS research · 2024-11-20Clinical Trial Update: Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia [EARLY_Phase 1]
Early-phase clinical trial of allogeneic CD19-targeted CAR-γδT cell infusion therapy for relapsed/refractory B-cell acute lymphoblastic leuk…